Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

References

• McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, et al. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 2006; 97: 247–54
   PubMed Web of Science ®Google Scholar
• See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429–35
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod D, Iversen P, Morris T, Carroll K, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–70
   PubMed Web of Science ®Google Scholar
• Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, et al. A randomised comparison of bicalutamide (‘Casodex’) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. Eur Urol 2002; 42: 204–11
   PubMed Web of Science ®Google Scholar
• Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from Scandinavian Prostate Cancer Group study number 6. J Urol 2004; 172: 1871–6
   PubMed Web of Science ®Google Scholar
• Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146–51
   PubMed Web of Science ®Google Scholar
• Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235–46.
   PubMedGoogle Scholar
• Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? [Abstract]. BJU Int 2000;86((Suppl 3)):220.
   PubMedGoogle Scholar
• Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004; 22: 4109–18
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579–82
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004; 60: 476–83
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 2005; 47: 587–92
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdona S, De Placido S, D'Armiento M, Gallo A, Damiano R, et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005; 174: 2197–203
   PubMed Web of Science ®Google Scholar
• Perdona S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005; 6: 295–300
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23: 808–15
   PubMed Web of Science ®Google Scholar
• Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272–6
   PubMed Web of Science ®Google Scholar